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Abstract
Introduction: Growth hormone (GH) deficiency, either isolated or combined with other pituitary hormone deficiencies, is associated with 
increased mortality and abnormal body composition, particularly visceral adiposity. We aimed to investigate the effects of GH deficiency 
with or without sex steroid deficiencies on ultrasonographic visceral fat (VF) and cardiovascular risk markers in patients with hypopitui-
tarism on conventional hormone replacement therapy. 
Material and methods: Forty hypopituitarism patients (24 women, 16 men; mean age 48 ± 16.1 years) with GH deficiency and 15 age- and 
sex-matched healthy controls were included in this cross-sectional study. The patients were stable on conventional hormone replacement 
but they were not on GH therapy. Patients who had sex steroid replacement were classified as Group 1 (n = 19), and patients who did not 
use sex steroids were classified as Group 2 (n = 21). Anthropometric measurements were performed. VF in three regions, subcutaneous 
fat, and carotid intima-media thickness (CIMT) were measured. VF volume was calculated by using a formula. 
Results: Visceral fat volume and mean CIMT were significantly higher in patients than healthy controls (p = 0.001 and 0.019 respectively). 
Homocysteine and hs-CRP were higher in patients (p < 0.05). In males, VF volume and VF thickness measured between abdominal muscle 
and splenic vein were significantly correlated with CIMT (r = 0.54, p = 0.047 and r = 0.66, p = 0.010 respectively). Furthermore, there was 
a strong positive correlation between VF thickness in pararenal region and homocysteine (r = 0.74, p = 0.001) in males. 
Conclusions: VF volume evaluated by ultrasound can be accepted as a cause of subclinical atherosclerosis in GH deficient hypopituitary 
patients, particularly males. (Endokrynol Pol 2014; 65 (3): 195–202)
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Streszczenie
Wstęp: Niedobór hormonu wzrostu (GH, growth hormone) może występować jako zaburzenie izolowane lub współistnieć z niedoborami innych 
hormonów przysadki. Wszyscy pacjenci z niedoborem GH są jednak obarczeni większym ryzykiem zgonu i mają nieprawidłowy skład tkanek 
ciała, z tendencją do otyłości brzusznej. Celem pracy była ocena zależności pomiędzy niedoborem GH, niezależnie od ewentualnego współistnienia 
niedoborów hormonów płciowych a grubością tkanki tłuszczowej trzewnej (VF, visceral fat) mierzoną metodą ultrasonograficzną oraz czynnikami 
ryzyka sercowo-naczyniowego u pacjentów z niedoczynnością przysadki, leczonych konwencjonalnymi preparatami hormonalnymi. 
Materiał i metody: Badanie miało charakter przekrojowy i zakwalifikowano do niego 40 pacjentów z niedoczynnością przysadki i nie-
doborem GH, w tym 24 kobiety, 16 mężczyzn; średni wiek badanych wynosił 48 ± 16,1 lat. Do badania włączono też 15 osób w grupie 
kontrolnej, dobranych pod względem płci i wieku do osób z grupy badanej. Pacjenci w grupie badanej leczeni byli konwencjonalnie 
preparatami hormonalnymi, ale nie otrzymywali hormonu wzrostu. Pacjenci leczeni hormonami płciowymi zostali włączeni do grupy 
1 (n = 19), a pacjenci nie otrzymujący takich preparatów do grupy 2 (n = 21). U wszystkich wykonano badania antropometryczne. Wy-
konywano pomiar grubości VF w trzech miejscach, badano grubość podskórnej tkanki tłuszczowej oraz grubość warstwy wewnętrznej 
i środkowej ściany tętnicy szyjnej (CIMT, carotid intima-media thickness). Objętość VF wyliczano według wzoru. 
Wyniki: U pacjentów w grupie badanej stwierdzono znamiennie większą objętość trzewnej tkanki tłuszczowej i średnią wartość CIMT 
w porównaniu z osobami zdrowymi (odpowiednio p = 0,001 i p = 0,019). Stężenie homocysteiny i hs-CRP były również większe w grupie 
badanej (p < 0,05). U mężczyzn stwierdzono istotną korelację pomiędzy objętością VF i grubością VF mierzoną pomiędzy mięśniami 
brzucha a żyłą śledzionową a wartością CIMT (odpowiednio r = 0,54 i p = 0,047 oraz r = 0,66 i p = 0,010). Ponadto, u mężczyzn stwier-
dzono wyraźną zależność pomiędzy grubością VF w okolicy nerek a stężeniem homocysteiny (r = 0,74 i p = 0,001). 
Wnioski: Objętość VF mierzona ultrasonograficznie może być wykładnikiem subklinicznie toczącej się miażdżycy u pacjentów z nie-
doborem hormonu wzrostu na skutek niedoczynności przysadki, w szczególności u mężczyzn. (Endokrynol Pol 2014; 65 (3): 195–202)
Słowa kluczowe: niedoczynność przysadki; tkanka tłuszczowa trzewna; ultrasonografia; miażdżyca
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Introduction
Hypopituitarism is characterised by the loss of function 
of the anterior pituitary gland. It is a rare condition that 
can present at any age and is caused by pathology of 
the hypothalamic-pituitary axis or by genetic muta-
tions [1]. The symptoms and signs of the disease may 
be non-specific or related to the underlying disease 
or to the hormone deficiencies [1]. Cardiovascular 
mortality is increased in adults with hypopituitarism 
[2, 3]. A number of aetiologies for the excess mortality 
associated with hypopituitarism have been determined 
as growth hormone (GH) deficiency [4] and untreated 
gonadotropin deficiency [3]. 
GH deficiency is associated with a cluster of car-
diovascular risk factors, including central adiposity 
[5], increased visceral fat [6], and dyslipidaemia [7]. An 
unfavourable lipid profile is important in the pathogen-
esis of atherosclerosis, and changes in lipids as in GH 
deficient patients may help to explain the increased 
cardiovascular risk in these patients [8]. 
High sensitivity C-reactive protein (hs-CRP), a 
serum marker of inflammation, has been consid-
ered to play an important role in chronic low grade 
inflammation and atherosclerotic process [9]. There 
has been data concerning the relationship between 
elevated homocysteine levels and cardiovascular 
risk [10]. 
Carotid intima–media thickness (CIMT) is an effec-
tive and non-invasive procedure for the evaluation of 
cardiovascular risk. Increased carotid arterial IMT has 
been reported in hypopituitarism patients with GH 
deficiency [11, 12]. 
Visceral fat thickness can be evaluated accurately 
with computerised tomography (CT) and magnetic 
resonance imaging (MRI) [13]. Both techniques have 
some limitations such as radiation exposure for CT 
and cost-effectiveness for MRI. Abdominal ultra-
sound (US) is an accurate, non-invasive and cost-
effective method for VF evaluation. But it has been 
found that visceral fat volume measured by US has 
a similar accuracy compared to the CT [14]. So, ultra-
sonographic VF evaluation has been determined as 
a useful method for the assessment of cardiovascular 
and metabolic risk [15]. 
The aim of this study was to investigate the ef-
fects of GH deficiency with or without sex steroid 
deficiencies on ultrasonographic visceral fat (VF) and 
cardiovascular risk markers such as hs-CRP, CIMT, 
serum lipids and homocysteine in patients with 
hypopituitarism who are on conventional hormone 
replacement. To the best of our knowledge, there is 
limited data about VF measurement by US in patients 
with hypopituitarism.
Material and method
Subjects
This prospective cross-sectional study was carried out 
between February 2009 and March 2011. The study 
group consisted of 40 patients (24 females, 16 males, 
mean aged 48 ± 16.1 years) who were admitted to An-
kara Numune Training and Research Hospital, Endocri-
nology and Metabolism Department. Also, 15 age- and 
sex-matched healthy subjects constituted our control 
group. The patient group had panhypopituitarism due 
to pituitary and/or hypothalamic disease such as pitui-
tary surgery, empty sellae, Sheehan syndrome and were 
on conventional hormone replacement therapy such as 
glucocorticoids, thyroid hormones and gonadotropins. 
Since L-Arginine was not found in Turkey, GH 
deficiency was diagnosed based on GH response to 
insulin tolerance test (ITT) (n = 20) if a patient had no 
contraindication such as age over 65 years, history of 
cardiovascular disease or epilepsy, or an IGF-1 level 
more than 5 percentiles below the age-specific normal 
range in a patient with at least two documented anterior 
pituitary hormone deficiencies (n = 20). After overnight 
fasting, ITT was performed using regular insulin (i.v.) 
at doses of 0.1 U/kg, and serum glucose and GH lev-
els were measured before and after 30, 45, 60, 90 and 
120 min. Serum glucose was measured < 2.2 mmol/L at 
the moment of hypoglycaemia. GH deficiency was de-
fined as a GH peak of less than 3 ng /mL on stimulation. 
Height of hypophysis equal to or less than 3 mm on 
MRI was accepted as empty sellae syndrome. Subjects 
on thyroid hormone, gonadotropins, and/or glucocor-
ticoid replacement therapy were required to receive 
stable replacement doses for at least three months 
before entry into the study. 
Exclusion criteria included history of acromegaly, 
active Cushing’s disease, unstable coronary artery or 
cerebrovascular disease within one year of entry into 
the study, GH therapy, pregnancy, breast-feeding, 
surgery or radiotherapy to the pituitary gland due to 
acromegaly, congestive heart failure, and uncontrolled 
diabetes mellitus. 
Height and weight were measured in light cloth-
ing wearing no shoes, and body mass index (BMI) was 
calculated as weight (kg)/height (m)2. Waist circumfer-
ence (WC) was measured at the umbilicus level in the 
standing position. 
The underlying causes of panhypopituitarism were 
as follows: 20 patients (50%) with surgery for pituitary 
adenoma, 14 patients (35%) with empty sellae, one pa-
tient (2.5%) with compression due to pituitary tumour, 
two patients (5%) with no cause named as idiopathic, 
and three patients (7.5%) with Sheehan’s syndrome. 
In all patients, hormone deficiencies were replaced 
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with levothyroxine, glucocorticoids, and desmopressin 
acetate. All sex hormone-deficient males were receiving 
testosterone. Female patients ≤ 40 years of age were 
currently receiving sex steroids. In order to exclude sex 
steroid deficiency on VF and cardiovascular risk mark-
ers, patients were divided into two groups. Patients who 
had sex steroid replacement were classified as Group 
1, and patients who did not use sex steroids were clas-
sified as Group 2. Statistical analyses were performed 
between the three groups, i.e. controls, Group 1 and 
Group 2. 
This study was approved by the ethics committee 
and the institutional review board of Ankara Numune 
Training and Research Hospital, and written informed 
consent was obtained from each subject. 
Biochemical analyses
Serum insulin like growth factor 1 (IGF-1) levels were 
measured by the auto analyser method (Immulite 
2000 XPI), anterior hypophyseal hormones like GH, 
thyroid stimulating hormone (TSH), follicular stimu-
lating hormone (FSH), luteinising hormone (LH), 
prolactin, adreno corticotrophic hormone (ACTH) 
and the target tissue hormone (fT4, fT3, oestradiol, 
total testosterone, free testosterone, cortisol) concen-
trations were evaluated by the auto analyser method 
(Adriacentaur). Fasting venous blood samples were 
collected, promptly centrifuged, and analysed within 
hours. Lipid parameters i.e. total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), triglyceride 
(TG), low-density lipoprotein cholesterol (LDL-C), 
uric acid, and high-sensitive CRP were measured by 
the photometric method (Unicel DxC 800, Beckman 
Coulter auto analyser). Fasting glucose was measured 
with a spectrophotometric analyser (Unicel DxC 800, 
Beckman). Serum homocysteine was measured with 
chemi-luminescence immunometric assay (Immulite 
1000) and fibrinogen was evaluated with the coagula-
metric method (SYSMEX CA 7000). 
Measurement of visceral and subcutaneous fat
Ultrasonography (Toshiba Aplio Ultrasound Imaging 
System, Japan) was performed after overnight fasting 
and visceral fat was measured at the end of a normal 
exhalation in the supine position. For each patient, 
a total of four measurements was obtained, as fol-
lows: i) the distance between the internal surface of 
the splenic vein and the abdominal muscle; ii) thick-
ness of the fat layer of the posterior right renal wall 
in the right posterior perinephric space; iii) distance 
between the internal surface of the abdominal muscle 
and the posterior wall of the aorta on the umbilicus; 
and iv) the thickness of preperitoneal and subcu-
taneous fat layers in the xiphoid process [14]. The 
visceral fat volume was calculated by using an equa-
tion as follows: [visceral fat volume] = –9.008+1.191 
× [distance between the internal surface of the 
abdominal muscle and the splenic vein (mm)] + 
0.987 × [distance between the internal surface of the 
abdominal muscle and the posterior wall of the aorta 
on the umbilicus (mm)] + 3.644 × [thickness of the 
fat layer of the posterior right renal wall (mm)] [14]. 
A 3.75-MHz convex-array probe was used to meas-
ure each parameter except the thickness of both the 
subcutaneous and the preperitoneal fat layers, which 
was measured using a 7.5 MHz linear-array probe 
by performing a longitudinal scan. The procedures 
were performed by the same experienced radiologist 
(S.S.K). The intra-examination coefficient of varia-
tion (within-subject variation from measurement to 
measurement) for US was 1%. To assess the reliability 
and reproducibility of US, five participants were 
selected and these measurements were repeated at 
the same time after one day by the same investigator. 
Within 95% confidence limits, intra class correlation 
coefficient was 97.6 for US. This assessment showed 
reliability and reproducibility of our measurements. 
Measurement of carotid artery intima media 
thickness
Intima-media thickness (IMT) of the carotid arteries was 
measured by ultrasound in the supine position by the 
same experienced investigator. High resolution B-mode 
ultrasound images (Loqic 3, General Electric, USA) 
with a 11 MHz linear array transducer were applied 
for IMT measurement. Three arterial wall segments in 
each carotid artery were imaged from a fixed lateral 
transducer angle at the far wall. The mean IMT over the 
three segments of both carotid arteries was calculated 
and designated as mean IMT. 
Statistical analyses
Normal distributions of the quantitative variables were 
analysed by Kolmogorov-Smirnov test. Parametric tests 
were applied when variables distributed normally and 
non-parametric tests were applied when variables did 
not distribute normally. Parametric test results were 
given as means ± standard deviations (SD). Non-
parametric test results were given as means, minimum-
maximum. Qualitative variables were presented as 
counts and proportions. For normally distributed vari-
ables, ANOVA was applied to evaluate the differences 
among groups and the Bonferoni test was as used for 
post hoc analysis. Comparison of variables which did 
not distribute normally was performed by using the 
Kruskal-Wallis test. To evaluate the correlation between 
the visceral fat measurements and the cardiovascular 
risk variables, Pearson∕Spearman correlation analysis 
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was used. A p value < 0.05 was considered as statisti-
cally significant. Statistical analysis was performed us-
ing the SPSS version 18.0 software (SPSS Inc., Chicago, 
IL, USA). 
Results
Baseline characteristics of patients and controls are 
summarised in Table I. Mean serum IGF-1 concentration 
in the patient group was 101.9 ± 90.0 ng/mL. Median 
disease time was 4 (range: 1–22) years. Mean disease 
duration was 3.7 ± 2.7 years for Group 1 and 5.9 ± 5.7 
years for Group 2 (p = 0.35). Mean peak level of GH 
response to ITT in all patients was < 3 ng/mL, which 
is accepted as GH deficiency. 
Baseline laboratory characteristics according to the 
three groups are summarised in Table II. There was no 
significant difference for BMI in the three groups. The 
glucose and HDL-C were similar in Group 1, Group 2 
and controls. Mean TG, Total-C, LDL-C, homocysteine 
and hs-CRP levels were significantly higher in the 
patients than in the controls (p < 0.05). Moreover, 
total-C levels were significantly higher in group 2 than 
either the patients in group 1 or the controls. TG and 
LDL-C levels were similar in the two patient groups. 
Hs-CRP and homocsyteine levels were significantly 
lower in controls than the patients. However, there 
was no statistically significant difference in hs-CRP 
and homocsyteine levels between the two patient 
groups (Table II). 
Subcutaneous fat thickness was similar in the three 
groups. Visceral fat thickness of three areas, VF volume, 
and CIMT were significantly lower in the controls that 
the patients (Table III). However, there was no signifi-
cant difference in these parameters between Groups 1 
and 2 (p > 0.05). 
Table I. Baseline characteristics of GH deficient patients and controls
Tabela I. Ogólna charakterystyka pacjentów z niedoborem hormonu wzrostu i osób w grupie kontrolnej
Characteristic Patients  
(n = 40)
Controls  
(n = 15) 
p
Age (year) 48 ± 16.2 39.9 ± 5.0 0.092
BMI [kg/m2] 28.6 ± 5.1 31.5 ± 5.9 0.094
Waist circumference [cm] 97.2 ± 13.5 103.2 ± 13.3 0.121
Fasting glucose [mg/dL] 78.3 ± 8.8 80.5 ± 11.3 0.563
Total cholesterol [mg/dL] 237.3 ± 67.3 169.1 ± 23.2 < 0.001*
Triglyceride [mg/dL] 220.5 ± 185.7 107.8 ± 60.7 0.001*
HDL-cholesterol [mg/dL] 44.1 ± 13.2 42.2 ± 10.6 0.692
LDL-cholesterol [mg/dL] 149.3 ± 47.5 105.2 ± 16.9 < 0.001*
Homocysteine [µmol/L] 13.8 ± 7.0 7.7 ± 2.9 < 0.001*
Hs-CRP [mg/dL] 2.3 ± 2.9 0.2 ± 0.3 < 0.001*
Variables are expressed as means ± SD. HDL — high-density lipoprotein; LDL — low-density lipoprotein; hs-CRP — high-sensitivity C-reactive protein; *p < 0.05 
Table II. Comparison of the characteristics of GH deficient patients in Group 1 (patients with sex steroid replacement), and 
Group 2 (patients without sex steroid replacement), and controls
Tabela II. Zestawienie danych pacjentów z niedoborem hormonu wzrostu w grupie 1 (pacjenci leczeni hormonami płciowymi), 
grupie 2 (pacjenci nieleczeni hormonami płciowymi) i osób w grupie kontrolnej
Characteristic Group 1 
(n = 19)
Group 2 
(n = 21)
Controls  
(n = 15) 
p 
Fasting glucose [mg/dL] 77.5 ± 7.0 78.9 ± 10.4 80.5 ± 11.3 0.688
Total cholesterol [mg/dL] 222.7 ± 43.3 251.1 ± 83.0 169.1 ± 23.2 0.001*
Triglyceride [mg/dL] 170.9 ± 76.2 267.6 ± 242.2 107.8 ± 60.7 0.015*
HDL-cholesterol [mg/dL] 40.3 ± 14.8 47.7 ± 10.6 42.2 ± 10.6 0.161
LDL-cholesterol [mg/dL] 147.3 ± 35.4 151.0 ± 57.6 105.2 ± 16.9 0.004*
Homocysteine [µmol/L] 13.7 ± 4.6 13.9 ± 8.8 7.7 ± 2.9 0.009*
Hs-CRP [mg/dL] 2.4 ± 3.0 2.3 ± 3.0 0.2 ± 0.3 0.027*
Variables are expressed as means ± SD. HDL — high-density lipoprotein; LDL — low-density lipoprotein; hs-CRP — high-sensitivity C-reactive protein; *p < 0.05 
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The patients’ characteristics according to gender 
are summarised in Table IV. There was no significant 
difference between the two genders. Distribution of 
subcutaneous fat, visceral fat, and CIMT was also inves-
tigated in female and male hypopituitarism patients. VF 
thickness measured between abdominal muscle-splenic 
vein distance was significantly increased in males but 
not in females (p = 0.044) (Table V). 
Correlation analyses were performed in females 
and males. There were significant positive correla-
tions between CIMT and visceral fat thickness of 
abdominal muscle-splenic vein distance (r = 0.66, 
Table V. Distribution of subcutaneous fat, visceral fat, and carotid artery IMT (CIMT) in hypopituitary patients according 
to gender
Tabela V. Rozkład grubości podskórnej tkanki tłuszczowej, tkanki tłuszczowej trzewnej i grubości błony wewnętrznej 
i środkowej (IMT) tętnicy szyjnej (CIMT) u pacjentów z niedoczynnością przysadki w zależności od płci
Variable Female 
(n = 24)
Male  
(n = 16)
p 
Subcutaneous fat thickness [mm] 28.9 ± 8.9 31.0 ± 10.6 0.638
Abdominal muscle-splenic vein distance [mm] 56.0 ± 12.8 63.1 ± 14.4 0.044*
Abdominal muscle-aorta distance [mm] 79.0 ± 16.8 82.9 ± 21.4 0.555
Pararenal fat thickness [mm] 14.5 ± 6.3 18.3 ± 7.6 0.064
Visceral fat volume [mm2] 188.2 ± 46.3 215.9 ± 58.9 0.215
Carotid intima media thickness [mm] 0.8 ± 0.2 0.7 ± 0.1 0.848
Variables are expressed as means ± SD; *p < 0.05
Table III. Distribution of subcutaneous fat, visceral fat, and carotid artery IMT (CIMT) in Group 1, Group 2 and controls
Tabela III. Rozkład grubości podskórnej tkanki tłuszczowej, tkanki tłuszczowej trzewnej i grubości błony wewnętrznej 
i środkowej (IMT) tętnicy szyjnej (CIMT) w grupach 1 i 2 oraz grupie kontrolnej
Variable Group 1 
(n = 19)
Group 2 
(n = 21)
Controls 
(n = 15)
p 
Subcutaneous fat thickness [mm] 31.9 ± 9.2 27.5 ± 9.5 29.3 ± 9.2 0.347
Abdominal muscle-splenic vein distance [mm] 60.7 ± 14.6 56.6 ± 12.7 42.7 ± 9.4 0.001*
Abdominal muscle-aorta distance [mm] 77.7 ± 21.6 83.1 ± 14.6 45.7 ± 16.7 0.001*
Pararenal fat thickness [mm] 17.4 ± 8.3 14.5 ± 5.0 11.7 ± 4.7 0.040*
Visceral fat volume [mm2] 204.2 ± 63.5 192.6 ± 39.0 129.5 ± 38.2 0.001*
Carotid intima media thickness [mm] 0.8 ± 0.1 0.8 ± 0.2 0.6 ± 0.1 0.019*
Variables are expressed as means ± SD; *p < 0.05
Table IV. Comparison of basal characteristics in hypopituitary patients according to gender
Tabela IV. Zestawienie badanych parametrów u pacjentów z niedoczynnością przysadki w zależności od wieku
Characteristic Female 
(n = 24)
Male 
(n = 16)
p
Age (year) 51.3 ± 15.9 43.1 ± 15.7 0.122
BMI [kg/m2] 29.0 ± 4.6 28.0 ± 5.8 0.456
Waist circumference [cm] 98.9 ± 10.7 94.6 ± 17.0 0.189
Fasting glucose [mg/dL] 79.1 ± 10.0 77.0 ± 6.9 0.692
Total cholesterol [mg/dL] 343.9 ± 77.9 227.8 ± 49.3 0.539
Triglyceride [mg/dL] 250.9 ± 230.0 176.8 ± 79.3 0.648
HDL-cholesterol [mg/dL] 47.0 ± 11.9 40.1 ± 14.3 0.067
LDL-cholesterol [mg/dL] 145.5 ± 53.5 154.6 ± 36.3 0.416
Homocysteine [µmol/L] 13.6 ± 6.8 14.3 ± 7.7 0.783
Hs-CRP [mg/dL] 2.4 ± 3.1 2.3 ± 2.8 0.851
Variables are expressed as means ± SD. HDL — high-density lipoprotein; LDL — low-density lipoprotein; hs-CRP — high-sensitivity C-reactive protein; *p < 0.05 
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p = 0.010) (Fig. 1) and also CIMT and visceral fat 
volume (r = 0.54, p = 0.047) (Fig. 2) in males. Ho-
mocysteine levels were significantly correlated with 
pararenal fat thickness (r = 0.79, p = 0.001) (Fig. 
3) and visceral fat volume (r = 0.66, p = 0.015) in 
males. However, there was no significant correlation 
between these parameters in females. 
Discussion
The present study revealed that GH deficient hypopi-
tuitary patients who are under conventional hormone 
replacement therapy with or without sex-steroids have 
significantly increased visceral fat thickness and volume 
evaluated by ultrasound in three different abdominal 
regions compared to healthy controls, despite similar 
body mass indexes. Furthermore, this study found 
that male hypopituitary patients with GH deficiency 
showed a significant association between VF thickness 
and well-known indicators of subclinical atherosclerosis 
such as CIMT and homocysteine. 
Epidemiological studies have demonstrated that 
hypopituitarism is associated with an increased risk 
of cardiovascular events, and GH deficiency has been 
hypothesised to be a contributory factor [4, 16]. The 
mechanisms underlying the effects of GH deficiency 
on the cardiovascular system may include effects on 
inflammatory pathways. Although atherosclerosis is 
a multifactorial disease, inflammation plays a central 
role in the pathophysiology of atherosclerosis [17]. 
Accordingly, as an inflammatory marker, hs-CRP was 
found to be higher in patients with GH deficiency than 
healthy controls in our study. In addition, moderate 
Figure 1. Relation between carotid intima media thickness and distance 
between abdominal muscle and splenic vein (r = 0.66, p = 0.010)
Rycina 1. Zależność pomiędzy grubością blaszki wewnętrznej 
i środkowej tętnicy szyjnej a odległością pomiędzy mięśniami 
brzucha i żyłą śledzionową (r = 0,66, p = 0,010)
Figure 2. Relation between carotid intima media thickness and 
visceral fat volume (r = 0.54, p = 0.047)
Rycina 2. Zależność pomiędzy grubością blaszki wewnętrznej 
i środkowej tętnicy szyjnej a objętością tkanki tłuszczowej trzewnej 
(r = 0,54, p = 0,047)
Figure 3. Relation between homocysteine and pararenal fat 
thickness (r = 0.79, p = 0.001)
Rycina 3. Zależność pomiędzy stężeniem homocysteiny 
a grubością torebki tłuszczowej nerki (r = 0,79, p = 0,001)
elevations in homocysteine levels are assumed to play 
a role in the risk of cardiovascular events [10]. As ex-
pected, we found elevated homocysteine levels in the 
patients with GH deficiency. 
Fat distribution is important in the assessment of 
cardiovascular and metabolic risk. The mechanism of 
increased metabolic risk is assumed to be related to adi-
pose tissue in the visceral region which is metabolically 
active [18–20]. Anthropometric measurements, such as 
weight or BMI, are not sufficient to evaluate visceral 
adiposity. It is known that WC is a traditional method 
used to measure metabolic risk [21]. WC is an important 
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risk factor for cardiovascular diseases regardless of the 
increased weight [22]. WC measurement is a practical, 
non-invasive, simple, and widely used method but it 
has a limitation. It evaluates not only visceral fat but 
also subcutaneous fat. So in order to detect visceral 
obesity, it is better to perform abdominal images such 
as CT, MRI, dual energy X-ray absorptiometry (DEXA) 
or US. Of these methods, CT is the most useful [23, 24]. 
However, both CT and MRI have some limitations such 
as high ionising radiation for the first method and less 
cost-effectiveness for the second. The DEXA method 
is also able to assess regional fat mass in conditions of 
minimal exposure to radiation [25]. Therefore, alterna-
tive, simple, non-invasive methods of assessing vis-
ceral fat accumulation are needed. Ultrasonography is 
a reliable and simple way for evaluating visceral and 
subcutaneous fat [14, 26–28]. Hirooka et al. demon-
strated a technique for the measurement of visceral fat 
volume by ultrasonography and compared this with 
the volume measured by CT [14]. The same authors 
suggested that the measurement of VF volume using 
US could be as effective as using CT. We used the same 
technique in patients with hypopituitarism in order to 
evaluate VF thickness and volume. It is obvious that 
growth hormone and oestrogen deficiencies are as-
sociated with increased visceral fat in hypopituitarism 
patients. There have been a few studies concerning 
VF evaluation in hypopituitarism patients with GH 
deficiency [29–31]. VF was evaluated by CT in most 
of the previous studies about GH deficiency. We used 
ultrasonography for evaluating VF as a non-invasive 
and accurate method in hypopituitarism. In the present 
study, VF thickness and volume were found to be inc-
reased in three different abdominal regions in patients 
with GH deficiency and hypopituitarism compared to 
healthy controls.
Homocysteine and CIMT are well-known markers 
of subclinical inflammation and atherogenesis. CIMT 
measured by high resolution B-mode ultrasonography 
is a non-invasive marker of subclinical atherosclerosis 
that has been used widely in vascular health assess-
ment both in adults and children [32–34]. It has been 
suggested that assessment of abdominal visceral fat 
by US predicts the presence and severity of coronary 
artery disease in clinical practice [15, 35, 36]. Kim et al. 
investigated VF thickness measured by US in diabetic 
patients (240 men and 106 women) and found correla-
tions between VF and HDL-C , hs-CRP concentrations 
and the intima-media thickness at the common carotid 
artery [15]. They emphasised that VF thickness might be 
a reliable index for assessing the amount of visceral fat 
and for identifying diabetic patients, particularly men, 
who are at high risk of cardiovascular disease. In the 
present study, a positive significant correlation between 
VF thickness, CIMT and homocysteine levels was found 
in the male patients with GH deficiency. 
This study had several limitations. The number of 
our study patients was not large, since hypopituitarism 
patients with GH deficiency constitute a small propor-
tion of the general population. Although VF thickness in 
men reasonably reflected atherosclerotic risk, it did not 
do so in women. This can be explained by the genetics of 
males in the Turkish population. Age, gender, genetics, 
and ethnicity are broad etiological factors contributing 
to variations in visceral adipose tissue accumulation and 
also cardiovascular risk. As a result, additional work is 
needed to validate using ultrasonographic VF thickness 
with larger groups of subjects in both sexes.
Conclusions
VF evaluation is important in GH deficient patients for 
the evaluation of atherosclerosis. GH deficient hypopi-
tuitary patients, with or without sex steroid deficiencies, 
have increased visceral fat volume compared to healthy 
controls. Additionally, the results confirm the useful-
ness of ultrasonographic VF volume assessment in GH 
deficient patients. Finally, these results indicate that 
excessive visceral fat accumulation affects the growth 
of subclinical atherosclerosis in GH deficient men. 
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